Ana Clara Duarte Dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Clara Duarte Dos Santos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ariela Dutra Norberto de Oliveira
Universidade Federal Fluminense
1 shared publication - Camille Nigri Cursino
Universidade Federal Fluminense
1 shared publication - Dulce Helena Nunes Couto
Instituto Nacional de Câncer José Alencar Gomes da Silva
1 shared publication - Jessica Pronestino de Lima Moreira
Universidade Federal Fluminense
1 shared publication - Larissa Rodrigues Nascimento
Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
1 shared publication - Larissa dos Santos Sebould Marinho
Universidade Federal Fluminense
1 shared publication
Latest Publications
- 27 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial
Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.
- 27 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial
Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.